Form 8-K · Current Report · Filed 2026-05-07
IQVIA Announces $2 Billion Increase in Share Repurchase Authorization
IQVIA Holdings Inc. announced on May 7, 2026, that its board of directors has authorized an additional $2 billion for the repurchase of the company's common stock under its existing equity repurchase program. This increase brings the total remaining authorization to $3.2 billion. The repurchase program, which does not obligate the company to repurchase any particular amount of stock, may be modified, extended, suspended, or discontinued at any time. The timing and amount of repurchases are determined by the company's management based on various factors including market price, corporate requirements, and market conditions. Purchases may be made in open market transactions, block trades, or privately negotiated transactions. The program has no expiration date, and the company may also repurchase stock through private or other transactions outside of the program. IQVIA may discontinue repurchases without notice at any time.
- Filer
- Iqvia Holdings Inc. IQV · NYSE
- Filed
- Accession
- 0001193125-26-212463
- CIK
- 0001478242
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Reported Item
Market reaction
Close before filing
$176.47
Next session
+1.3%
Since filing
+33.2%
Latest close
$235.02
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from IQV reporting the same item, with the next session's move:
Insider tape
Within 45 days of this filing, IQV insiders reported 4 Form 4 transactions — net buying of $143K.
About Iqvia Holdings Inc.
Iqvia Holdings Inc. is a leading global provider of advanced analytics, technology solutions, and contract research services. Its primary function is to support the healthcare sector by offering data-driven insights and innovations that underpin strategic decision-making across pharmaceutical, biotechnology, and medical device industries. Iqvia plays a crucial role in facilitating drug development through its comprehensive clinical research capabilities, encompassing everything from clinical trials to regulatory submissions. Additionally, its technology solutions leverage artificial intelligence and machine learning to optimize clinical and commercial operations, contributing to enhanced patient outcomes and streamlined healthcare delivery. Iqvia's integrated services impact sectors such as drug safety, patient engagement, and real-world evidence, making it an indispensable partner for healthcare companies seeking to navigate complex markets and regulatory environments. Globally recognized for its vast data repository and cutting-edge analytical platforms, Iqvia serves as a pivotal player in the transformation of the healthcare landscape, empowering organizations to accelerate innovation and improve patient care.
Never miss another IQV filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.